Let’s Talk Compliance: What the July 3rd Ruling on FTC Non-Compete Ban Means for the Health Care Industry
About this episode
The episode discusses the implications of the July 3rd ruling on the FTC's Non-compete Ban for the health care and life sciences industry.
In this episode, Benjamin Dryden, vice chair of Foley’s Antitrust & Competition Practice Group and David McMillan, managing principal of consulting and chief financial officer at PYA, discuss the recent July 3rd ruling on the U.S. Federal Trade Commission’s (FTC) Non-compete Ban and how this will affect the health care & life sciences industry.
People in this episode
Guest: David McMillan
Topics covered
- FTC Non-compete Ban
- health care industry
- antitrust
- competition
Keywords
- compliance
- health care law
- life sciences
More episodes of Health Care Law Today Podcast
- Chanda Center for Health: Reimagining Access to and Delivery of Long-term Disability Care
- Let’s Talk Compliance: The Risks and Pitfalls of Health Care Supply Chain Compliance
- Let’s Talk Compliance: Physician Compensation Plans and Trends of 2024
- Let’s Talk Compliance: Health Care Organizations Take Note: Trends and Pitfalls in the Bond Market Compliance Space
- Let’s Talk Compliance: What the FTC’s Ban on Non-Competes Means for the Health Care Industry
- Health Care Philanthropy: Navigating the Hurdles, Rules, and Restrictions
Explore listener stats, chart rankings, contacts and more on the Health Care Law Today Podcast podcast page.